Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

>

Phase 1b/2 Study of Voreloxin in Combination with Cytarabine in Relapsed/Refractory AML

Researchers also presented interim data from an ongoing Phase 1b/2 clinical trial testing voreloxin in combination with cytarabine. The Phase 1b/2 trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered on days one and four with a fixed dose of cytarabine given either as a continuous infusion (Schedule A) or as a daily IV bolus (Schedule B) for five days.

To date, 45 patients have been treated in Schedule A and preliminary data is available for 38 patients in the dose escalation portion of the study. Nine of these 38 patients have achieved a CR or CRp in voreloxin dose cohorts ranging from 20 to 90 mg/m(2). Complete remissions have been observed in both relapsed and in treatment refractory AML patients. Schedule A has also been generally well tolerated with an acceptable safety profile in this heavily pretreated population. A maximum tolerated dose (MTD) of 80 mg/m(2) of voreloxin was established for Schedule A, and AML patients in first relapse are now being enrolled at the MTD in the Phase 2 portion of this study.

Single agent cytarabine is the current treatment standard for relapsed AML patients dosed across a range of different dose levels administered by either bolus infusion or 24 hour continuous infusion with typical remission rates of approximately 20 percent. Schedule B was recently opened for enrollment with a starting dose of voreloxin at 70 mg/m(2) on days one and four. The first cohort of patients has been fully enrolled in Schedule B.

"Voreloxin has demonstrated anti-leukemic activity when administered in combination with cytarabine," said Judith E. Karp, M.D., Director, Adult Leukemia Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and an in
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Levi & ... Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning possible violations ... issued by the Company in connection with its study ... TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. ... or by telephone at (212) 363-7500, toll-free: (877) ...
(Date:3/27/2015)... 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, ... approved the grant of an aggregate of 236,070 options ... consultants of the Company pursuant to the Company,s Stock ... expire on the tenth anniversary of the date of ... anniversary of the date of grant and 50,000 are ...
(Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... , NEW YORK, Oct. 2 Business ... today released "The Role of ISO 9000 in Document ... certification for its Document Review Services, Quality Management System. ... developing a document review Quality Management System (QMS), where ...
... Oct. 1 Algos Therapeutics Inc., a Minnesota-based global ... of Dr. Ganesh Iyer as its new president and ... , "We were incredibly fortunate to have attracted such ... Algos," stated Gary Smaby, Algos Board Chair and managing ...
Cached Medicine Technology:BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes 'Quality Equals Defensibility' 2BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes 'Quality Equals Defensibility' 3Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO 2
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable ... Center in Omaha, Nebraska on Friday, May 8th and ... concert dates will be added in Omaha as Garth has ... , The Garth Brooks World Tour is continuing its run ... that Garth Brooks and Trisha Yearwood will bring their act ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... 2015 Smile Brands Inc. ( http://www.smilebrands.com ... support services to dental groups in the United States, ... Castle Dental office in Hendersonville, TN. , ... this new Castle Dental office provides families with a ... in comprehensive, quality dental care. Hendersonville marks the eleventh ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3
... Common Office Environments StudiedBOULDER, Colo., May 11 ... company that provides comprehensive and cost-effective ergonomic interventions ... improve productivity, today announced that John Wiley and ... journals has published a book titled "Safety Manager,s ...
... an invited panelist in the second annual SOA in Healthcare conference to ... ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, Dave Shaver, will ... to be held on June 2 - 4 in Chicago, Illinois. ...
... - Easy-to-swallow formulation provides important new alternative for patientsRESEARCH ... GSK ) announced today that the U.S. Food ... Orally Disintegrating Tablets. Lamictal ODT uses a ... a tablet that has a pleasant taste and disintegrates ...
... 11 Lambert, Edwards & Associates (LE&A) ... growing roster of health care clients.Aspirus is a community-directed ... care services to residents in north-central Wisconsin and the ... is consistently recognized as one of the nation,s premier ...
... Services and ProCitius Research jointly announce a strategic alliance created to ... ... Toronto, Canada and Chennai, India (PRWEB) - Dalton Pharma ... provide clients with contract chemistry services of exceptional value. ...
... HHS Report Released During National Women,s Health Week Points ... new report released today on gender-based differences in mental ... men to suffer from major depression. The report ... the effect trauma and violence can have on long ...
Cached Medicine News:Health News:Office Ergonomics Book Reveals Early-Stage Solutions 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 2Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 4Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 5Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 6Health News:Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc. 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Health News:Women at Greater Risk for Depression and Anxiety 2Health News:Women at Greater Risk for Depression and Anxiety 3
Ideal for breast compression and contouring breast cups....
Ideal for breast compression with adjustable hook and eye closure....
Female Mini-VEST, Front Closure, X-Firm...
Male Support Brief...
Medicine Products: